UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 71

Sortiert nach

Clinical Perspectives on Liquid Biopsy in Metastatic Colorectal Cancer

Frontiers in genetics, 2021-01, Vol.12, p.634642-634642

2021

Volltextzugriff (PDF)

Prognostic values of regulatory T cells (Tregs) and Treg-related genes in gastric cancer

Central-European journal of immunology, 2023-01, Vol.48 (1), p.14-25

2023

Volltextzugriff (PDF)

Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer

Frontiers in oncology, 2022-09, Vol.12, p.850242-850242

2022

Volltextzugriff (PDF)

CMAB009 plus irinotecan versus irinotecan‐only as second‐line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild‐type metastatic colorectal cancer patients: promising findings from a prospective, open‐label, randomized, phase III trial

Cancer communications (London, England), 2019-05, Vol.39 (1), p.1-13

2019

Volltextzugriff (PDF)

Colorectal cancer subtyping and prognostic model construction based on interleukin-related genes

Physiological genomics, 2024-05, Vol.56 (5), p.367

2024

Volltextzugriff (PDF)

Association analyses of the JAK/STAT signaling pathway with the progression and prognosis of colon cancer

Oncology letters, 2019-01, Vol.17 (1), p.159-164

2019

Volltextzugriff (PDF)

Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double‐Blinded, Placebo‐Controlled, Randomized Phase III Trial (ALTER0703)

The oncologist (Dayton, Ohio), 2021-10, Vol.26 (10), p.e1693-e1703

2021

Volltextzugriff (PDF)

A phase I/II study of ASKB589 (anti-claudin 18.2 [CLDN18.2] monoclonal antibody) in patients with solid tumors

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.397-397

2023

Volltextzugriff (PDF)

Final survival results from a multicenter, randomized phase II trial of intravenous paclitaxel plus FOLFOX (ivPOF) and/or intraperitoneal paclitaxel plus FOLFOX (ipPOF) versus mFOLFOX6 as first-line treatment of advanced gastric cancer (AGC): SYLT/FNF 004

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4041-4041

2021

Volltextzugriff (PDF)

Proline-rich acidic protein 1 upregulates mitotic arrest deficient 1 to promote cisplatin-resistance of colorectal carcinoma by restraining mitotic checkpoint complex assembly

Journal of Cancer, 2023-01, Vol.14 (9), p.1515-1530

2023

Volltextzugriff (PDF)

[Corrigendum] Molecular heterogeneity of guanine nucleotide binding‑protein γ subunit 4 in left‑ and right‑sided colon cancer

Oncology letters, 2023-01, Vol.25 (1), Article 11

2023

Volltextzugriff (PDF)

MicroRNA-30c-2-3p represses malignant progression of gastric adenocarcinoma cells via targeting ARHGAP11A

Bioengineered, 2022-06, Vol.13 (6), p.14534-14544

2022

Volltextzugriff (PDF)

FOLFOX versus POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) as a first-line treatment in advanced gastric cancer (AGC): A multicenter, randomized phase II trial, FNF-004 trial

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.6-6

2019

Volltextzugriff (PDF)

Molecular heterogeneity of guanine nucleotide binding-protein γ subunit 4 in left- and right-sided colon cancer

Oncology letters, 2020-12, Vol.20 (6), p.334-334, Article 334

2020

Volltextzugriff (PDF)

The efficacy and safety of anlotinib in refractory colorectal cancer: A double-blinded, placebo controlled, randomized phase III ALTER0703 trial

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.65-65

2021

Volltextzugriff (PDF)

POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) versus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): Update from a multicenter, randomized phase II trial, FNF-004 trial

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.4035-4035

2019

Volltextzugriff (PDF)

[Corrigendum] Molecular heterogeneity of guanine nucleotide binding‑protein γ subunit 4 in left‑ and right‑sided colon cancer

Oncology letters, 2021-01, Vol.21 (3), Article 227

2021

Volltextzugriff (PDF)

Erratum: Molecular heterogeneity of guanine nucleotide binding-protein γ subunit 4 in left- and right-sided colon cancer

Oncology letters, 2021-03, Vol.21 (3), p.227-227

2021

Volltextzugriff (PDF)

Neoadjuvant Chemotherapy plus Bevacizumab Combined with Total Mesorectal Excision in Treating Locally Advanced Rectal Cancer Patients with BRAF Mutation: Clinical Benefit and Safety

Computational and mathematical methods in medicine, 2021, Vol.2021, p.4227650-7

2021

Volltextzugriff (PDF)

Patient controlled analgesia (PCA) vs non-PCA intravenous hydromorphone titration for severe cancer pain: A multi-center, phase III trial, HMORCT09-1

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.12078-12078

2020

Volltextzugriff (PDF)

Comparing Patient-Controlled Analgesia Versus Non-PCA Hydromorphone Titration for Severe Cancer Pain: A Randomized Phase III Trial

Journal of the National Comprehensive Cancer Network, 2021-10, Vol.19 (10), p.1148

2021

Volltextzugriff (PDF)

The efficacy and toxicity of modified docetaxel, cisplatin and 5-fluorouracil combination therapy for 27 patients with advanced stage gastric adenocarcinoma

The Chinese-German journal of clinical oncology, 2010-07, Vol.9 (7), p.396-400

2010

Volltextzugriff (PDF)

Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study

Annals of translational medicine, 2020-10, Vol.8 (19), p.1233-1233

2020

Volltextzugriff (PDF)

Performance of Azure-winged magpies in Aesop's fable paradigm

Scientific reports, 2021-01, Vol.11 (1), p.804-804, Article 804

2021

Volltextzugriff (PDF)

Controllable depolymerization of lignin using carbocatalyst graphene oxide under mild conditions

Fuel (Guildford), 2020-05, Vol.267 (C), p.117100, Article 117100

2020

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(68)
Tagungsberichte
(3)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Clinical Perspectives on Liquid Biopsy in Metastatic Colorectal Cancer

Prognostic values of regulatory T cells (Tregs) and Treg-related genes in gastric cancer

Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer

CMAB009 plus irinotecan versus irinotecan‐only as second‐line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild‐type metastatic colorectal cancer patients: promising findings from a prospective, open‐label, randomized, phase III trial

Colorectal cancer subtyping and prognostic model construction based on interleukin-related genes

Association analyses of the JAK/STAT signaling pathway with the progression and prognosis of colon cancer

Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double‐Blinded, Placebo‐Controlled, Randomized Phase III Trial (ALTER0703)

A phase I/II study of ASKB589 (anti-claudin 18.2 [CLDN18.2] monoclonal antibody) in patients with solid tumors

Final survival results from a multicenter, randomized phase II trial of intravenous paclitaxel plus FOLFOX (ivPOF) and/or intraperitoneal paclitaxel plus FOLFOX (ipPOF) versus mFOLFOX6 as first-line treatment of advanced gastric cancer (AGC): SYLT/FNF 004

Proline-rich acidic protein 1 upregulates mitotic arrest deficient 1 to promote cisplatin-resistance of colorectal carcinoma by restraining mitotic checkpoint complex assembly

[Corrigendum] Molecular heterogeneity of guanine nucleotide binding‑protein γ subunit 4 in left‑ and right‑sided colon cancer

MicroRNA-30c-2-3p represses malignant progression of gastric adenocarcinoma cells via targeting ARHGAP11A

FOLFOX versus POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) as a first-line treatment in advanced gastric cancer (AGC): A multicenter, randomized phase II trial, FNF-004 trial

Molecular heterogeneity of guanine nucleotide binding-protein γ subunit 4 in left- and right-sided colon cancer

The efficacy and safety of anlotinib in refractory colorectal cancer: A double-blinded, placebo controlled, randomized phase III ALTER0703 trial

POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) versus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): Update from a multicenter, randomized phase II trial, FNF-004 trial

[Corrigendum] Molecular heterogeneity of guanine nucleotide binding‑protein γ subunit 4 in left‑ and right‑sided colon cancer

Erratum: Molecular heterogeneity of guanine nucleotide binding-protein γ subunit 4 in left- and right-sided colon cancer

Neoadjuvant Chemotherapy plus Bevacizumab Combined with Total Mesorectal Excision in Treating Locally Advanced Rectal Cancer Patients with BRAF Mutation: Clinical Benefit and Safety

Patient controlled analgesia (PCA) vs non-PCA intravenous hydromorphone titration for severe cancer pain: A multi-center, phase III trial, HMORCT09-1

Comparing Patient-Controlled Analgesia Versus Non-PCA Hydromorphone Titration for Severe Cancer Pain: A Randomized Phase III Trial

The efficacy and toxicity of modified docetaxel, cisplatin and 5-fluorouracil combination therapy for 27 patients with advanced stage gastric adenocarcinoma

Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study

Performance of Azure-winged magpies in Aesop's fable paradigm

Controllable depolymerization of lignin using carbocatalyst graphene oxide under mild conditions

Suchergebnisse filtern